GSK1292263
Cat. No.：YN320537
CAS No. ：1032823-75-8
| 产品名称: | GSK1292263 |
| CAS No.: | 1032823-75-8 |
| Chemical Name: | 5-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]methoxy]-2-[4-(methylsulfonyl)phenyl]-pyridine |
| Synonyms: | GSK1292263; GSK 1292263l; GSK-1292263 |
| 分子量: | 456.56 |
| 分子式: | C₂₃H₂₈N₄O₄S |
| SMILES: | CC(C1=NOC(N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(C)(=O)=O)=N1)C |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | GSK-1292263 是一种有效的，具有口服活性的 GPR119 激动剂，作用于人和大鼠 GPR119，pEC50分别为 6.9 和 6.7。GSK-1292263 可用于 2 型糖尿病 (T2DM) 的研究。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Park, Y.H., Choi, H.H., Lee, D.H., et al.YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse modelArch. Pharm. Res.40(6),772-782(2017)
Yang, J.W., Kim, H.S., Im, J.H., et al.GPR119: A promising target for nonalcoholic fatty liver diseaseFASEB J.30(1),324-335(2016)
Polli, J.W., Hussey, E., Bush, M., et al.Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: From in vitro data to clinical study designXenobiotica43(6),(2013)
